Diabetes drug reduces OSA severity in adults with obesity, study shows
The finding could be good news for people who don't like wearing a CPAP mask to bed.
Type 2 diabetes drug tirzepatide has been shown to be effective in treating moderate to severe sleep apnoea in a worldwide clinical trial.
US researchers showed that tirzepatide (Mounjaro) — a GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist (RA) — can significantly lowers breathing interruptions during sleep, a key indicator of obstructive sleep apnoea (OSA) severity.
